Androgen Receptor
AR (androgen receptor) is a member of steroid hormone receptor and ligand-activated transcription factor. It plays a crucial role in prostate cellular proliferation and male sexual differentiation.
Products Related to Androgen Receptor(159)
- GC61491(R)-BicalutamideCAS: 113299-40-4Purity: >98.00%
(R)-Bicalutamide is the (R)-enantiomer of Bicalutamide. (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer.
- GC62061Melengestrol acetateCAS: 2919-66-6Purity: >99.50%
Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity.
- GC62106JNJ-63576253CAS: 2110428-64-1Purity: >99.00%
JNJ-63576253 (TRC-253) is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the research of castration-resistant prostate cancer (CRPC).
- GC62329VPC-14449CAS: 1621375-32-3Purity: >98.50%
VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer.
- GC62603Ralaniten triacetateCAS: 1637573-04-6Purity: >98.50%
Ralaniten triacetate (EPI-506), the pro-drug of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7.
- GC62683RalanitenCAS: 1203490-23-6Purity: >99.50%
Ralaniten (EPI-002) is a potent and orally active antagonist of the androgen receptor-N-terminal domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC50 of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC).
- GC63217Testosterone undecanoateCAS: 5949-44-0Purity: >98.00%
Testosterone undecanoate, an orally administered ester prodrug of the anabolic steroid of testosterone, acts as an effective testosterone replacement therapy.
- GC63292(rac)-PF-998425CAS: 1076225-26-7Purity: >98%
(Rac)-PF-998425 is a potent, selective, nonsteroidal androgen receptor (AR) antagonist.
- GC63402RezvilutamideCAS: 1572045-62-5Purity: >99.50%
Rezvilutamide (SHR3680) is an androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer.
- GC64540Ar-V7-IN-1CAS: 2230880-25-6Purity: >99.00%
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications, in particular cancers such as prostate cancer (extracted from patent WO2018114781A1, compound 43).
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC61481 | PROTAC AR Degrader-4 TFA | - | >98.00% | |
| GC61491 | (R)-Bicalutamide | 113299-40-4 | >98.00% | |
(R)-Bicalutamide is the (R)-enantiomer of Bicalutamide. (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer. | ||||
| GC61850 | Medroxyprogesterone acetate D3 | - | >98.00% | |
| GC61971 | Liarozole | 115575-11-6 | >98.50% | |
Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). | ||||
| GC62061 | Melengestrol acetate | 2919-66-6 | >99.50% | |
Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity. | ||||
| GC62106 | JNJ-63576253 | 2110428-64-1 | >99.00% | |
JNJ-63576253 (TRC-253) is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the research of castration-resistant prostate cancer (CRPC). | ||||
| GC62118 | ARV-110 | 2222112-77-6 | >99.00% | |
ARV-110 is an orally bioavailable, specific androgen receptor (AR) PROTAC degrader that leads to ubiquitination and degradation of AR. | ||||
| GC62124 | UT-34 | 2168525-92-4 | >98.00% | |
UT-34 is a potent, selective and orally active second-generation pan-androgen receptor (AR) antagonist and degrader with IC50s of 211.7 nM, 262.4 nM and 215.7 nM for wild-type, F876L and W741L AR, respectively. | ||||
| GC62209 | CLP-3094 | 312749-73-8 | >99.00% | |
CLP-3094 is a potent BF3 (binding function 3)-directed inhibitor of the androgen receptor (AR). | ||||
| GC62249 | Honokiol DCA | 1620160-42-0 | >98% | |
| GC62329 | VPC-14449 | 1621375-32-3 | >98.50% | |
VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer. | ||||
| GC62603 | Ralaniten triacetate | 1637573-04-6 | >98.50% | |
Ralaniten triacetate (EPI-506), the pro-drug of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7. | ||||
| GC62683 | Ralaniten | 1203490-23-6 | >99.50% | |
Ralaniten (EPI-002) is a potent and orally active antagonist of the androgen receptor-N-terminal domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC50 of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC). | ||||
| GC63066 | Methenolone acetate | 434-05-9 | >99.50% | |
| GC63096 | Nandrolone phenylpropionate | 62-90-8 | >98.00% | |
| GC63217 | Testosterone undecanoate | 5949-44-0 | >98.00% | |
Testosterone undecanoate, an orally administered ester prodrug of the anabolic steroid of testosterone, acts as an effective testosterone replacement therapy. | ||||
| GC63292 | (rac)-PF-998425 | 1076225-26-7 | >98% | |
(Rac)-PF-998425 is a potent, selective, nonsteroidal androgen receptor (AR) antagonist. | ||||
| GC63402 | Rezvilutamide | 1572045-62-5 | >99.50% | |
Rezvilutamide (SHR3680) is an androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer. | ||||
| GC63579 | Linuron | 330-55-2 | >98.00% | |
Linuron is a phenylurea herbicide that is widely used to control the growth of grass and weeds in various agriculture crops and in orchards. | ||||
| GC63764 | 7-α-Methylthio Spironolactone-D3 | - | >98% | |
| GC63935 | Testosterone buciclate | 118931-19-4 | >98.00% | |
| GC64540 | Ar-V7-IN-1 | 2230880-25-6 | >99.00% | |
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications, in particular cancers such as prostate cancer (extracted from patent WO2018114781A1, compound 43). | ||||
| GC64586 | Nandrolone laurate | 26490-31-3 | >98% | |
| GC64600 | SK33 | 1928724-23-5 | >99.00% | |
SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity. | ||||
